Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry activity against hepatitis C
virus and entry and post-entry antiviral activity against duck hepatitis B virus (DHBV)
infection. REP 2055 has been shown to have potent prophylactic effect against HCV infection
in vivo and potent therapeutic effect against established DHBV infection in vivo
The REP 101 protocol is the first-in-man proof of concept study designed to investigate the
safety and antiviral activity of REP 2055 administration in human patients with chronic HBV
or HCV infection.